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Abstract
Background: Antipsychotic medications are routinely prescribed in nursing homes to address the behavioral and
psychological symptoms of dementia. Unfortunately, inappropriate prescribing of antipsychotic medications is common
and associated with increased morbidity, adverse drug events, and hospitalizations. Multifaceted interventions
can achieve a 12–20 % reduction in antipsychotic prescribing levels in nursing homes. Effective interventions
have featured educational outreach and ongoing performance feedback.
Methods/Design: This pragmatic, cluster-randomized control trial and embedded process evaluation seeks to
determine the effect of adding academic detailing to audit and feedback on prescribing of antipsychotic medications
in nursing homes, compared with audit and feedback alone. Nursing homes within pre-determined regions of Ontario,
Canada, are eligible if they express an interest in the intervention. The academic detailing intervention will be delivered
by registered health professionals following an intensive training program including relevant clinical issues and
techniques to support health professional behavior change. Physicians in both groups will have the opportunity
to access confidential reports summarizing their prescribing patterns for antipsychotics in comparison to the local
and provincial average. Participating homes will be allocated to one of the two arms of the study (active/full intervention
versus standard audit and feedback) in two waves, with a 2:1 allocation ratio. Homes will be randomized after stratifying
for geography, baseline antipsychotic prescription rates, and size, to ensure a balance of characteristics. The primary
outcome is antipsychotic dispensing in nursing homes, measured 6 months after allocation; secondary outcomes
include clinical outcomes and healthcare utilization.
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Discussion: Policy-makers and the public have taken note that antipsychotics are used in nursing homes in Ontario far
more than other jurisdictions. Academic detailing can be an effective technique to address challenges in appropriate
prescribing in nursing homes, but effect sizes vary widely. This opportunistic, policy-driven evaluation, embedded within
a government-initiated demonstration project, was designed to ensure policy-makers receive the best evidence possible
regarding whether and how to scale up the intervention.
Trial registration: ClinicalTrials.gov NLM Identifier: NCT02604056.
Keywords: Academic detailing, Antipsychotic medication, Inappropriate prescribing, Nursing home, Randomized trials
Background
Nursing home residents are at a greater risk for in-
appropriate prescribing as they are more fragile, receive
interventions from multiple point-of-care staff, and are
unable to detect errors in their medication [1]. Inap-
propriate prescribing is often linked to polypharmacy
and to subsequent adverse outcomes such as increased
hospital admissions, increased morbidity, and impaired
functionality [2, 3]. In particular, antipsychotic medi-
cations (APMs) are known to be associated with car-
diovascular events, parkinsonism, falls, and death [4].
Furthermore, APMs are associated with increased mor-
bidity and mortality among elderly residents with de-
mentia [5], signaling the pressing need for solutions to
mitigate inappropriate use and encourage appropriate
pharmacological and non-pharmacological manage-
ment of symptoms. In Ontario, Canada, APM pres-
cription rates in nursing homes range from 0 to 67 %,
with an average of 33 % of nursing home residents
using an APM [6]. Nursing home administration and
government officials are facing increasing public and
media scrutiny [7] as rates are more than double those
in the USA.
Interventions to reduce inappropriate prescribing of
APMs among people with dementia in nursing homes have
achieved reductions in APM prescribing levels between 12
and 20 % [5]. In a systematic review of interventions to
optimize prescribing in nursing homes, academic detailing
had the strongest evidence for improvements in pre-
scribing, whereas audit and feedback (AF) interventions
had a small to moderate impact on physician practices
[1]. For educational interventions to be effective at im-
proving inappropriate prescribing, recommendations
suggest they must be implemented through techniques
that engage health professionals to consider behavior
change, such as academic detailing [1, 8]. AF can act as
a complementary strategy by drawing attention to gaps
between actual and desired performance, priming the
recipients to respond to educational interventions [8].
One prior randomized controlled trial combining quarterly
AF plus education around quality improvement demon-
strated an overall decrease in resident falls, behavioral
symptoms, and pressure ulcers, including among low-risk
residents, compared to a control group receiving neither
intervention [9].
In Ontario, Canada, policy-makers, including the
Ontario Ministry of Health and Long-Term Care
(MOHLTC) and Ontario Medical Association (OMA),
established an appropriate prescribing working group
which is tasked to make recommendations on oppor-
tunities to improve prescribing in Ontario. One pro-
ject that has emerged from this working group is the
Appropriate Prescribing Demonstration Project, which
involves the evaluation of an academic detailing inter-
vention in nursing homes. Members of the project
team are accountable to the policy-makers, and the
evaluation approach required policy-maker approval.
This partnership and pragmatic evaluation of a policy-
maker-driven initiative increases the likelihood that
the embedded evaluation will achieve an impact on
health service delivery and policy [10]. We designed a
pragmatic, cluster-randomized controlled trial that
seeks to assess the impact of the intervention with an
embedded, mixed methods process evaluation to
understand how and why intervention effects were ob-
served and provide insights regarding scale-up.
Methods/Design
A pragmatic, cluster-randomized controlled trial with
an embedded process evaluation of the Appropriate
Prescribing Demonstration Project will be undertaken
and includes both summative and formative compo-
nents. The protocol received ethics approval from the
University of Toronto and Women’s College Hospital
Research Ethics Boards. The trial is registered on
ClinicalTrials.gov (NLM Identifier: NCT02604056).
Setting
In the province of Ontario, many healthcare services
are covered under the Ontario Health Insurance Pro-
gram (OHIP)—a government-run health plan that is
publicly funded. OHIP covers medically necessary ser-
vices provided by physicians, including basic and
emergency services, and specialist visits. Within nurs-
ing homes, all personal and nursing care is funded by
the government, while residents are responsible for
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accommodation charges such as room and board. Ac-
commodation costs are set by the MOHLTC and are
standard across the province of Ontario. Rate reduc-
tions are available through a government subsidy for
those with low income on a case-by-case basis. The
Ontario Drug Benefit Program covers prescription
drug costs for individuals who reside in nursing
homes, including some nutritional products and dia-
betic testing agents, provided they are prescribed by
an Ontario doctor or other authorized prescriber.
Trial design
The effectiveness of the intervention will be evaluated
using a two arm, pragmatic, cluster-randomized trial, with
nursing homes allocated to the full, active intervention
(featuring academic detailing offered to each prescriber
and team members in the home) or standard quality im-
provement supports with blinded outcome analysis of
administrative data after 6 months. The standard quality
improvement supports, which includes individualized AF
reports administered by Health Quality Ontario (HQO),
represent “usual care” as this initiative has been launched
province-wide and therefore a concurrent control arm
with no exposure to a quality improvement intervention is
not feasible.
Eligibility
Nursing homes within pre-determined regions of Ontario
will be eligible if they expressed an interest in the full
intervention. These regions, or hubs, were chosen because
they contain a wide variety of nursing home types within a
reasonable travel distance (i.e., <100 km). To be eligible
for participation, the medical and administrative leads of
the nursing homes must agree to and support the project.
Exclusion criteria include nursing homes without any
prescribers caring for at least 10 residents routinely or
nursing homes with fewer than 30 residents.
Recruitment
A general recruitment email will be distributed by the
OMA and MOHLTC to eligible home administrative leads
and from other stakeholders (i.e., local physician leads) to
medical directors of eligible nursing homes. Identification
of additional homes will be done in collaboration with the
Local Health Integration Networks and other stakeholders.
The entire nursing home is considered a research par-
ticipant and so explicit, written consent will be obtained
from the medical director and administrative leads from
each home. Individual providers and staff members in
the home can decide whether and when to engage with
the academic detailing intervention.
Allocation
Participating nursing homes will be allocated to one of
the two arms of the study (active/full intervention versus
standard AF), with an intended 2:1 allocation ratio. The
intervention will be administered in two waves to
optimize resource use (i.e., gradual training and phasing-
in of program delivery staff ) (refer to Fig. 1); therefore,
homes will be allocated to the intervention in two waves.
Nursing homes that share prescribers will be grouped
together and allocated as a unit to avoid contamination.
Homes (or groups of homes) will be randomized in two
waves after stratifying for geography, as well as baseline
APM prescription rates and size (categorized as above or
below the median), to promote a balance of characteris-
tics between the two arms. A 2:1 allocation ratio will be
used to promote recruitment and to satisfy the require-
ments of the trial sponsor without drastically affecting
sample size requirements. Allocation will be conducted
by an independent statistician blinded to home identity
using computer-generated random numbers.
Interventions
Standard quality improvement supports/usual care
Policy-makers previously determined that all nursing
home physicians in the province would be provided
with the opportunity to access online practice reports
(serving as AF) that would confidentially describe their
prescribing practices for APMs, compared to regional
and provincial data representing their (de-identified)
peers. Starting in autumn 2015, in concert with the ini-
tiative outlined in this proposal, HQO will be produ-
cing confidential practice reports using data from the
Institute for Clinical Evaluative Sciences (ICES), a not-
for-profit research institute with a secure and accessible
array of Ontario’s health-related data, to describe selected
quality indicators for physicians working in nursing homes.
This will initially focus on appropriate prescribing of APM
for older men and women and provides data on how their
APM use compares to others in the province. The report
also includes additional information regarding the clinical
and demographic features of their nursing home resident
roster. Receipt of the reports is voluntary. To receive the
reports, physicians must sign up and confirm their iden-
tity. They will then receive updated reports quarterly,
which they can download from HQO’s secure website. In
addition, HQO will be launching voluntary, virtual “com-
munities of practice” to enable sharing of best practices
across homes and providers throughout the province.
Academic detailing (active intervention)
The academic detailing intervention will be delivered by
registered health professionals (e.g., nurses or pharmacists)
who have received intensive training to support providers
in nursing homes, to address challenges and opportunities
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Fig. 1 Flow of participants
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to improving prescribing practices and overall quality
of care. Academic detailing is a method of service-
oriented educational outreach for front-line clinicians
which combines the interactive, one-on-one communi-
cation approach of industry detailers with the evidence-
based, non-commercial information of academia [11].
The intervention requires the Academic Detailers to
have direct and ongoing contact with the nursing
homes including administrators, providers, and staff
from the time of launch through to program comple-
tion. Given the diverse target audiences that will likely
be engaged within the homes, the Academic Detailer
will work to understand the context, barriers, capacity,
and needs of each home to ensure the service being
provided by the detailer is relevant, meaningful, and ap-
propriate. The intervention then includes the provision
of the following different “types” of visits made by the
Academic Detailer: meetings (likely with administrators
or home leadership to describe the program and value),
presentation (large group, inter-professional audience),
group visit (typically 2–6 providers), and one-on-one visits
(“traditional” academic detailing visits). In addition, the
Academic Detailer provides important service to the
nursing homes and providers between visits (i.e., by
responding to questions via email or phone) to respond
to the needs and build trust/credibility over time. To
optimize resource allocation, the academic detailing inter-
vention will be administered in two waves (October 2015
and February 2016), each lasting a duration of 6 months.
The Centre for Effective Practice, a Toronto-based federal
non-profit organization retained by the OMA/MOHLTC
based on their experience with academic detailing, will
manage the academic detailing intervention. Best practices
in training of the Academic Detailers and in the execution
of the program will be applied (refer to Appendix). Given
the nature of the program as a demonstration project for
the purposes of understanding feasibility in the Ontario
context, it is critical to ensure a pragmatic approach to the
delivery of the intervention. Therefore, the number of visits
per provider or home per topic and the length of visits will
not be pre-defined or standardized. Intervention fidelity
and acceptability metrics will be evaluated through the em-
bedded process evaluation.
Data collection
Outcomes will be assessed using population-level ad-
ministrative databases linked through unique, encrypted
patient identifiers at the ICES. Data will be compiled
from the following databases: (1) the Ontario Drug Benefits
(ODB) database, covering all prescription medications dis-
pensed to residents in nursing homes; (2) the Canadian
Institute for Health Information (CIHI) databases covering
all inpatient hospitalizations and emergency department
visits; (3) the Ontario Health Insurance Plan (OHIP)
database, covering physician billings for procedures and
consultations; (4) the Registered Persons Database covering
demographic information including date of death; and (5)
the Continuing Care Reporting System (CCRS) database
for clinical and demographic information on nursing
homes residents collected using the Resident Assess-
ment Instrument (RAI). Each nursing home resident in
the province receives a “full” RAI assessment within
2 weeks from admission date, every 12 months from pre-
vious full assessment or any other time when the clinical
condition of a resident changed considerably. Each resi-
dent also receives a shorter “quarterly” assessment every
3 months. For each resident, the CCRS database holds
demographic and clinical information, including data re-
garding clinical diagnoses (e.g., dementia, psychosis), dis-
pensing of APMs, and occurrences of falls. In addition, a
number of validated outcome scales can be derived from
the CCRS data, including those related to activities of daily
living (ADLs), aggressive behaviour, pain, and mood.
Outcomes
The primary prescribing outcome is the number of days
the resident was provided an APM in the previous
week, as determined from the CCRS database. Secondary
prescribing outcomes include mean APM dose (over the
previous month) and prevalence of antipsychotic, benzo-
diazepine, antidepressant, and acetaminophen prescribing
(defined as any prescription during the previous month),
as determined from the ODB database. All primary and
secondary prescribing outcomes will be assessed at
baseline (pre-intervention) and at 3 and 6 months post
intervention. Baseline is defined as the week or month im-
mediately prior to randomization, while post-intervention
measurements are defined as the third and sixth months
after randomization. These outcomes will be assessed on
all residents who are alive at the time of the assessment
and who were present in the home for the full duration
of the prior week/month (i.e., repeated cross-sectional
within-cluster data).
Secondary clinical outcomes will be extracted from the
RAI, including ADLs (measured by the ADL long-form
scale) [12]; pain (pain scale) [13]; depression (depression
rating scale) [14]; number of falls in the past month; and
the extent of aggressive behaviour [15]. These will be
assessed at baseline and at 3 and 6 months post inter-
vention. The most current data collected immediately
prior to the implementation of the intervention, and at
each post-randomization time point, will be used, re-
gardless of mortality status at the subsequent time point.
Health care utilization outcomes will be assessed at
baseline and at 6 months post intervention and include
the number of ER visits and hospitalizations during the
previous 6 months. A longer duration is required to
allow adequate time for the intervention to have an
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effect on these outcomes. All residents present in the
homes at any time during the study will contribute to
the analysis using person-time of follow-up.
Data analysis
Outcome evaluations will use de-identified data available
from the ICES and will be conducted by analysts blinded
to group allocation. All evaluations will be reported at
the aggregate level, and the confidentiality of nursing
homes, residents, and providers will be protected.
Impact of the intervention on clinical outcomes
Descriptive statistics will be calculated for all variables of
interest: continuous variables with a normal distribution
will be described using means and standard deviations
(medians and inter-quartile ranges will be used in the
case of skewed distributions), whereas categorical vari-
ables will be summarized using frequencies and propor-
tions. All analyses will be conducted under the principles
of intention-to-treat analysis and will be conducted using
SAS v.9.3. Statistical significance will be assessed at the
5 % level.
The primary outcome (days dispensed APM in the
previous week) measured at baseline, 3 months, and
6 months will be analyzed using generalized linear mixed
effects regression with multinomial distribution and cu-
mulative logit link. The fixed effects of time, interven-
tion, and intervention by time will be the main variables
of interest. To account for the staggered implementation
of the intervention, wave will be included as a fixed ef-
fect. Random intercepts and slopes will be specified to
account for intracluster and inter-period correlations.
To maximize statistical efficiency, the analysis of pre-
scribing outcomes will adjust for the stratification factors
(hub, baseline APM prescription rates, and size) as well
as public/private home ownership and the following resi-
dent covariates: age, sex, levels of function, and aggressive
behaviour (using multiple imputation for missing covari-
ates if necessary). The proportional odds assumption will
be evaluated using the score test. The effect of the
intervention at 6 months will be expressed as cumula-
tive odds ratio (OR) with 95 % confidence interval (CI),
which expresses the odds of having fewer days with
APM dispensed in the intervention arm compared to
the control arm.
The dichotomous prescribing outcomes (i.e., any APM
prescription in the last month) at baseline, 3 months,
and 6 months will be analyzed using generalized linear
mixed effects regression with binomial distribution and
logit link function. Fixed and random effects will be spe-
cified as described for the primary outcome. The fixed
effects of time, intervention, and intervention by time
will be the main variables of interest. Dose equivalent of
APM dispensed in the past month at baseline, 3 months,
and 6 months will be analyzed using linear mixed effects
regression with normal distribution and identity link.
Fixed and random effects will be specified as described
for the primary outcome. The effect of the intervention
will be described as difference in change from baseline
to 6 months using adjusted least square means with
95 % CI.
Secondary clinical outcomes measured as continuous
variables (e.g., ADL, depression score) will be analyzed
using linear mixed effects regression with normal distri-
bution and identity link. Fixed and random effects will
be specified as described for the prescribing outcomes.
The effect of the intervention will be expressed as adjusted
least square mean differences with 95 % CI. Secondary
clinical outcomes measured on an ordinal scale (e.g., pain
scale) at baseline, 3 months, and 6 months will be ana-
lyzed using generalized mixed effects regression as de-
scribed for the primary outcome but using multinomial
distribution and cumulative logit link. Presence of any falls
in the past 30 days will be analyzed at baseline, 3 months,
and 6 months using generalized linear mixed effects re-
gression with binomial distribution and logit link, as de-
scribed for the primary outcome. In the intention-to-treat
analyses for the secondary clinical outcomes (e.g., ADL,
falls, pain), the potential effect on inferences of residents
who died will be examined using sensitivity analyses under
conservative assumptions: for example, residents who
died during the interval will be assigned the worst pos-
sible score. Depending on the extent of resident turn-
over within homes, additional analyses for primary and
secondary outcomes will explore inclusion of subject-
specific random effects to account for repeated measures
on the same resident over time (i.e., a cohort rather than
cross-sectional design).
Health care utilization outcomes will be analyzed at
6 months using generalized linear mixed effects regres-
sion with Poisson or negative binomial distribution and
log-link, with log person-time of follow-up as an offset
term. The following fixed effects will be included: inter-
vention, phase, and stratification variables, as well as the
rate of health care utilization at the home 6 months
prior to the intervention. Resident covariates will be ad-
justed for as specified for the primary outcome. Home
will be included as a random effect.
The effect of the intervention will be expressed as ad-
justed rate ratio (RR) with 95 % CI. Potential effect
modification by home ownership status, size of the
home (<65 beds, 65–129 beds, or >129 beds), location
(urban/rural), specialist utilization (proportion of resi-
dents with geriatrician or psychiatrist consultation
within 6 months), plus primary physician characteristics
(sex, years of experience), as well as resident characteris-
tics (age, sex, history of psychosis, diagnosis of dementia,
time at facility, levels of function, and aggressive
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behaviour, plus whether a geriatrician or psychiatrist pro-
vided a consult) will be explored by including interactions
between these variables and treatment. A planned sensi-
tivity analysis will restrict the academic detailing cohort to
physicians who also accessed the AF to examine for syn-
ergy (i.e., interaction) in the full intervention group.
Economic evaluation
We will work with the program delivery teams to deter-
mine the costs for start-up and implementation. Average
costs will be presented as $/nursing home, $/nursing
home physician, and $/nursing home resident. A cost-
benefit analysis will compare costs of the intervention
with direct savings related to changes in prescribing (if any)
as well as the cost per type of clinical outcome achieved
(e.g., $/Rx change). A more detailed economic evaluation
modelling overall health care costs was considered out
of scope.
Power calculation
Our target sample size of 60 nursing homes was deter-
mined primarily by pragmatic considerations and logis-
tical constraints. Specifically, the contract between the
MOHLTC and the Centre for Effective Practice specified
that 40 nursing homes would receive academic detailing.
After grouping homes sharing physicians together, we
anticipate a total of 45 independent clusters. For our pri-
mary outcome measured as an ordinal variable (number
of days with APM prescription in the past 7 days), 45
clusters with 2:1 allocation will yield 80 % power to de-
tect a minimally important difference (cumulative odds
ratio) of 0.6, assuming an intracluster correlation coeffi-
cient (ICC) of 0.01 and an average of 120 residents per
home. If we found that 30 % of control arm residents
have 7 days of APM prescriptions, a cumulative odds ra-
tio of 0.6 would correspond to an absolute reduction of
10 % in this proportion.
To ensure adequate power to detect a clinically im-
portant difference in our secondary prescribing outcome,
we used a simulation study with 1000 simulation runs to
determine the required effect size. Assuming a conserva-
tive ICC of 0.1, an average of 120 residents per home, and
a control arm proportion of 30 %, we will have 83.4 %
power to detect an OR of approximately 0.75 for our sec-
ondary prescribing outcome at 6 months (corresponding
to a reduction in the intervention arm to approximately
25 %).
Embedded process evaluation
The process evaluation involves a mixed methods approach
using quantitative prescriber surveys, document analysis,
and individual qualitative interviews. To understand the in-
tervention’s mechanism of change, we will survey partici-
pating clinicians and nursing home administrators in both
groups prior to intervention delivery and again 6 months
later to measure theoretical constructs targeted by our
intervention and changes in these constructs associated
with the intervention [16]. We will assess constructs
based on the COM-B model (capability, opportunity,
and motivation) [17], which are specifically targeted by
the intervention. These constructs will be assessed for
each of the targeted clinical behaviours. Questions will
include validated items from the Determinants of Im-
plementation Behaviour Questionnaire [18] as well as
measurements of self-efficacy and coping planning, two
factors which have been shown to influence clinician
behaviour [19].
To evaluate how and why the intervention achieved
the effects observed, we will employ an embedded single
case design with cross case synthesis to gain an in-depth
understanding of intervention fidelity, the mechanisms
of action, and the conditions and factors associated with
implementation of the intervention. The embedded de-
sign enables the examination of interactive processes
and contextual features through various units of analysis
derived from a structured approach to develop a pro-
gram theory [20–22]. The Consolidated Framework for
Implementation Research (CFIR) [23] and Normalization
Process Theory (NPT) [24] will be used to guide and
structure data collection methods and data analysis. The
CFIR provides a comprehensive taxonomy of defined
constructs that are likely to influence implementation
[23]. Its application facilitates the identification of active
components and further explores the setting in which the
intervention is delivered. NPT is an established framework
for understanding how and whether complex interven-
tions become embedded in health care practice—that is,
normalized [24]. The inclusion of both frameworks pro-
vides a complementary approach as the application of
CFIR helps to capture contextual factors that influence
implementation and effectiveness while NPT facilitates
the understanding of the mechanisms that underlie sus-
tained impact. This approach is ideally suited to this study
as it entails numerous individuals, professionals, unit, and
organizational and health system features that may impact
the effectiveness of the AF + AD intervention in selected
nursing homes.
Recruitment
A quantitative survey will be administered by the re-
search team to the nursing home leadership across all
participating sites. At the time of study launch and after
6 months, the research team will distribute the survey,
asking home leadership to complete it themselves in
addition to forwarding the survey to the prescribers and
pharmacists. A series of weekly reminders to home leader-
ship will be sent using a modified Dillman approach [25],
for a total of 3 weeks, to encourage completion.
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A sub-sample of 4–5 nursing homes from the inter-
vention group (AF + AD) will be selected for the qualita-
tive process evaluation. These homes will be selected to
maximize sampling variation, including prescribing rates,
size, ownership, and resident characteristics. Initial contact
will be from the investigative team with each home’s
Senior Management and/or Director of Care/Nursing. A
member of the research team will inform participants of
the nature of the study, which is to understand how stake-
holders respond to and interact with the interventions, to
explore any unintended consequences, and to examine
experiences associated with the implementation of the
academic detailing intervention. As a first wave of recruit-
ment for health professionals in the embedded process
evaluation, the leadership team of each home will be asked
to distribute a letter of information via email about this
aspect of the larger study to the prescribing health profes-
sionals in the 4–5 facilities where the case studies will be
focused. The email message will have pertinent informa-
tion of the nature of the study. As a second phase of re-
cruitment, if response is less than 25 %, a member of the
research team will reach out to home administrators by
telephone. The third and final phase of recruitment will
consist of purposive sampling of prescribers and pharma-
cists associated with the home, using snowball techniques
to seek providers with various perspectives on APMs. This
method would entail existing participants to identify po-
tential participants among their known acquaintances. All
academic detailers will be invited to participate in an
interview.
Data collection
To understand the intervention’s mechanisms of change,
we will survey participating clinicians and nursing home
administrators in both groups prior to intervention de-
livery and again following the completion of the inter-
vention to measure theoretical constructs targeted by
our intervention and changes in these constructs associ-
ated with the intervention [16]. We will assess constructs
based on the COM-B model (capability, opportunity, and
motivation) [17], which are specifically targeted by the
intervention. These constructs will be assessed for each of
the targeted clinical behaviours. Questions will include
validated items from the Determinants of Implementation
Behaviour Questionnaire [18] as well as measurements of
self-efficacy and coping planning, two factors which have
been shown to influence clinician behaviour [19].
We will also interview home administrators and pre-
scribers, including physicians, nurse practitioners, and
consultant pharmacists. Interviews will be used to under-
stand how participants respond to and interact with the
interventions and also to explore their experiences associ-
ated with the implementation of the academic detailing
intervention, including any unintended consequences.
Academic Detailers will also be invited to participate in an
interview in order to explore their experiences associated
with the implementation of the academic detailing inter-
vention. The interviews will be guided by the detailed pro-
gram theory (which itself will be refined iteratively), the
CFIR [23], and NPT [24]. The interview guides will be
pilot tested prior to their full-scale use. It is expected in-
terviews will last between 30 and 90 min. Interviews will
be digitally audio taped and transcribed verbatim by an
external third party.
Data analysis
Analysis of baseline survey data will include descriptive
statistics and exploration of the association between
process variables and receiving the intervention as a pre-
liminary test of the program theory. This will be con-
ducted by a statistician without knowledge of group
allocation. Measures of capability, opportunity, and mo-
tivation will be calculated as the mean of the measure
item scores. We will use analytical methods previously
developed to test for differences between groups on hy-
pothesized targeted constructs, controlling for baseline
differences [16]. Mediation models will be used to test
whether intervention effects on behaviour are mediated
through the targeted theoretical constructs.
Training materials will be analyzed using Charmaz’s
textual analysis method [26] and compared to interview
findings to evaluate intervention fidelity. Interviews will
be analyzed using the framework method [27, 28], with
CFIR constructs applied as pre-defined deductive codes.
Open coding will be applied as required by the data to
allow for the emergence of themes not captured across
CFIR constructs. Qualitative findings will be considered
through the lens of NPT in order to identify potential
mechanisms by which the intervention’s observed effect
becomes part of routine practice. In the final analytical
phase, the research team will prepare a comprehensive
case study database with the datasets from each of the
research questions [29]. We will employ a variety of strat-
egies to ensure fidelity and credibility of the data: (1) using
multiple sources of data, writing a chain of evidence that
describes all elements of the case study database and a de-
scription of the derivation of the evidence from initial re-
search questions to ultimate case study conclusions, and
having key informants review the case study draft by
having collaborators participate in the triangulation
analysis and the return of findings (construct and exter-
nal validity); (2) examining points of convergence (pat-
tern matching) and divergence (examining alternative
explanations) within and among the various datasets
(internal validity through cross comparative analyses); and
(3) creating a case study database with a chain of evidence
and having a stepped analysis process whereby there is an
initial independent review of the data by at least three
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reviewers who then meet to reach consensus around the
common themes (reliability) [30]. The framework ap-
proach ensures a systematic approach to summarizing
and classifying the data, facilitating a comprehensive
review of participant narratives while encouraging a
higher-level conceptual analysis [28]. Interconnected
analytic stages allow for the constant refinement of
themes while moving toward the development of an
overarching conceptual framework of how the interven-
tion works and why.
Trial status
The first wave of detailing has been completed. The second
wave of intervention delivery commenced in March 2016.
Cases for the qualitative aspect of the process evaluation
were identified in February 2016, with interviews occurring
through February and March 2016.
Discussion
Ontario has one of the highest rates of APM prescriptions
in Canada, with approximately 30.5 % of nursing home
residents receiving inappropriately prescribed APMs in
the absence of diagnosed psychosis [31]. Nursing home
residents may receive up to four times as many prescrip-
tions compared to the elderly in the community [1], in-
creasing the risk of drug-to-drug interactions and adverse
outcomes [32, 33]. Prior research has indicated that in-
appropriate decision-making, limited knowledge of APM
risks and benefits, limited personnel, excess employment
of temporary nurses, and the employment of nurses with
weak interpersonal skills contribute to an increase in the
perceived need for psychotropic drug use [34]. To address
suboptimal prescribing practices, interventions must con-
sider these factors and support prescribers to implement
alternative approaches [8, 35].
In nursing homes and other settings, academic detail-
ing is an effective intervention to improve inappropriate
prescribing [1, 8]. However, the magnitude of effects ob-
served in studies varies widely and a local program
evaluation is needed to determine whether and how to
scale up the intervention. The results of the embedded
process evaluation will help identify the core compo-
nents and the contextual factors that influence its suc-
cess, providing an overarching understanding of how the
intervention works, for whom, and in what circum-
stances. By exploring both causal attribution and causal
explanation, this program evaluation will have significant
implications for healthcare administrators, government
agencies, and other stakeholders seeking to use academic
detailing, alone or combined with other quality improve-
ment strategies, to support large-scale initiatives to scale
up and support quality improvement.
Ethics approval and consent to participate
Ethics approval has been obtained from the University
of Toronto Research Ethics Board and the Women’s
College Hospital Research Ethics Board.
Appendix
Academic detailing best practices.
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